Andrea Portocarrero Castillo, MD
Gastroenterology · Mission
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Silvia Castillo Sy Mdpa · 3 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Castillo’s office at (956) 424-1511 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A181751 · Current
Licensed to practise in California · since 2022 · expires 2026-09-30 · Universidad Peruana Cayetano Heredia Facultad De Medicina Alberto Hurtado.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$67,765
Medicare paid this office $67,765 for 326 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 95 | $16,245 | $142 |
| New patient visit (60+ min) | 90 | $15,592 | $173 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 32 | $7,502 | $234 |
| Return visit (30+ min) | 46 | $5,502 | $102 |
| Biopsy of large bowel using a flexible endoscope | 36 | $3,565 | $99 |
See all 12 services
| Long return visit (40+ min) | 95 | $16,245 | $142 |
| New patient visit (60+ min) | 90 | $15,592 | $173 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 32 | $7,502 | $234 |
| Return visit (30+ min) | 46 | $5,502 | $102 |
| Biopsy of large bowel using a flexible endoscope | 36 | $3,565 | $99 |
| New patient visit (45+ min) | 32 | $3,397 | $106 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,688 | $117 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,089 | $91 |
| Short return visit (20+ min) | 19 | $1,427 | $71 |
| Study of rectum sensitivity and function | 12 | $939 | $78 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 15 | $223 | $15 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 36 | $172 | $5 |
Procedures Medicare counted
| Colonoscopy | 29 | More than 53% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 30 | More than 56% of doctors who do this |
Who their Medicare patients are
326 Original Medicare patients in 2024. Average age 72 · Under 65 14% · 85 and older 8% · Women 61% · Also on Medicaid 36% · Health risk score 1.60. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 66% · Diabetes 29% · Coronary heart disease 29% · Chronic kidney disease 25% · Depression 25% · Heart failure 18% · Cancer 18% · Atrial fibrillation 15% · COPD 13% · Stroke 11% · Dementia 10%.
The office billed $555,020, Medicare allowed $88,817 and paid $67,765; for 567 services of 35 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 326 | 567 | 72 | 1.60 | $555,020 | $67,765 |
| 2023 | 285 | 564 | 71 | 1.89 | $525,772 | $61,315 |
| 2022 | 46 | 68 | 75 | 1.62 | $64,824 | $7,791 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| New patient visit (60+ min) | 76 | $10,111 | $133 |
| Long return visit (40+ min) | 56 | $8,978 | $125 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 31 | $6,696 | $216 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $4,674 | $117 |
| Biopsy of large bowel using a flexible endoscope | 32 | $3,815 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $3,430 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $2,969 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,949 | $70 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $1,965 | $89 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,494 | $107 |
| New patient visit (45+ min) | 12 | $1,180 | $98 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $813 | $74 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 61 | $282 | $5 |
2022: 3 services
| New patient visit (60+ min) | 18 | $2,912 | $162 |
| Long return visit (40+ min) | 11 | $1,421 | $129 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 13 | $60 | $5 |
Medicaid work
$25,993 in 2024
Medicaid paid $25,993 for 277 billed services this clinician did in 2024, up to 29 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (60+ min) | 81 | $12,455 |
| COLONOSCOPY W/LESION REMOVAL | 27 | $7,085 |
| Upper gastrointestinal endoscopy with biopsy | 32 | $3,695 |
| TISSUE EXAM BY PATHOLOGIST | 57 | $2,259 |
| Fentanyl citrate injection | 41 | $298 |
| Injection, midazolam hydrochloride, per 1 mg | 39 | $202 |
| 2024 | 277 | 6 | 29 | $25,993 |
| 2023 | 213 | 7 | 24 | $20,583 |
| 2022 | 35 | 1 | 21 | $3,682 |
| 2021 | 60 | 3 | 15 | $2,633 |
| 2018 | 388 | 1 | 43 | $30,277 |
See the largest Medicaid services in earlier years
2023
| New patient visit (60+ min) | 57 | $7,159 |
| Upper gastrointestinal endoscopy with biopsy | 45 | $5,468 |
| COLONOSCOPY AND BIOPSY | 25 | $4,596 |
| Long return visit (40+ min) | 26 | $2,072 |
| TISSUE EXAM BY PATHOLOGIST | 19 | $980 |
| Fentanyl citrate injection | 28 | $240 |
| Injection, midazolam hydrochloride, per 1 mg | 13 | $68 |
2022
| New patient visit (60+ min) | 35 | $3,682 |
2021
| OFF/OP EST MAY X REQ PHY/QHP | 26 | $2,345 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 19 | $225 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 15 | $63 |
2018
| Hospital outpatient clinic visit for assessment and management of a patient | 388 | $30,277 |
Drugs they prescribed that Part D paid
$194,459
Pharmacies billed $194,459 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 637) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
404 generic and 233 brand-name prescriptions · $194,459 in drug cost · 14 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 170 | $144,188 | $848 |
| Motegrity | 11 | $10,342 | $940 |
| Dexlansoprazole Dr | 18 | $5,054 | $281 |
| Esomeprazole Magnesium | 34 | $2,896 | $85 |
| Peg 3350-Electrolyte | 47 | $1,014 | $22 |
See all 13 drugs
| Linzess | 170 | $144,188 | $848 |
| Motegrity | 11 | $10,342 | $940 |
| Dexlansoprazole Dr | 18 | $5,054 | $281 |
| Esomeprazole Magnesium | 34 | $2,896 | $85 |
| Peg 3350-Electrolyte | 47 | $1,014 | $22 |
| Pantoprazole | 40 | $828 | $21 |
| Omeprazole | 82 | $792 | $10 |
| Gavilyte-G | 34 | $712 | $21 |
| Famotidine | 60 | $449 | $7 |
| Dicyclomine | 19 | $350 | $18 |
| Peg-3350 and Electrolytes | 12 | $268 | $22 |
| Diphenoxylate-Atropine | 17 | $207 | $12 |
| Nortriptyline | 12 | $104 | $9 |
Year by year
| 2024 | 637 | 214 | 0% (0) | 37% | $194,459 |
| 2023 | 305 | 154 | 0% (0) | 23% | $44,311 |
| 2022 | 50 | 40 | 0% (0) | None | $5,361 |
| 2021 | 118 | 32 | 0% (0) | 12% | $153,327 |
| 2020 | 51 | 17 | 0% (0) | None | $78,796 |
| 2019 | 219 | 43 | None | None | $24,096 |
| 2018 | 1,308 | 77 | 4% (46) | 24% | $168,060 |
| 2017 | 257 | 60 | 5% (13) | 26% | $50,277 |
| 2016 | 31 | None | None | None | $1,857 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Linzess | 26 | $15,187 | $584 |
| Peg 3350-Electrolyte | 61 | $1,335 | $22 |
| Omeprazole | 57 | $1,146 | $20 |
| Gavilyte-G | 30 | $570 | $19 |
| Pantoprazole | 15 | $415 | $28 |
| Esomeprazole Magnesium | 11 | $358 | $33 |
| Famotidine | 16 | $189 | $12 |
2022: 1 drug
| Peg 3350-Electrolyte | 16 | $369 | $23 |
2021: 2 drugs
| Entecavir | 11 | $10,889 | $990 |
| Pantoprazole | 21 | $131 | $6 |
2020: 1 drug
| Pantoprazole | 19 | $279 | $15 |
2019: 6 drugs
| Gabapentin | 12 | $305 | $25 |
| Atorvastatin | 14 | $188 | $13 |
| Lisinopril | 17 | $139 | $8 |
| Losartan | 13 | $78 | $6 |
| Amlodipine Besylate | 13 | $75 | $6 |
| Hydrochlorothiazide | 12 | $73 | $6 |
2018: 34 drugs
| Victoza 3-Pak | 16 | $23,266 | $1,454 |
| Novolog Flexpen | 18 | $22,324 | $1,240 |
| Basaglar Kwikpen U-100 | 26 | $13,403 | $516 |
| Symbicort | 24 | $11,701 | $488 |
| Novolog | 21 | $7,435 | $354 |
| Gabapentin | 79 | $2,159 | $27 |
| Ventolin Hfa | 23 | $1,568 | $68 |
| Diclofenac | 19 | $1,566 | $82 |
| Morphine Sulfate Er | 28 | $1,151 | $41 |
| Atorvastatin | 81 | $1,048 | $13 |
| Metoprolol | 32 | $573 | $18 |
| Nifedipine Er | 13 | $460 | $35 |
| Oxycodone-Acetaminophen | 15 | $438 | $29 |
| Lisinopril | 81 | $428 | $5 |
| Amlodipine Besylate | 61 | $382 | $6 |
| Omeprazole | 30 | $376 | $13 |
| Losartan | 33 | $322 | $10 |
| Ezetimibe | 11 | $321 | $29 |
| Rosuvastatin | 14 | $296 | $21 |
| Metformin Hcl Er | 28 | $234 | $8 |
| Hydrochlorothiazide | 43 | $218 | $5 |
| Cyclobenzaprine | 13 | $208 | $16 |
| Tizanidine | 20 | $197 | $10 |
| Isosorbide Mononitrate Er | 11 | $162 | $15 |
| Metoprolol | 23 | $153 | $7 |
| Furosemide | 31 | $153 | $5 |
| Hydralazine | 12 | $136 | $11 |
| Metformin | 19 | $130 | $7 |
| Fluticasone Propionate | 11 | $101 | $9 |
| Clopidogrel | 13 | $90 | $7 |
| Triamterene-Hydrochlorothiazid | 11 | $84 | $8 |
| Sertraline | 16 | $76 | $5 |
| Tamsulosin | 12 | $52 | $4 |
| Pantoprazole | 12 | $52 | $4 |
2017: 2 drugs
| Gabapentin | 15 | $488 | $33 |
| Pantoprazole | 12 | $69 | $6 |
Money from drug and device companies
$49 in 2023
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Keytruda | $49 | 2 payments
|
See all 2 published payments
| Merck Sharp & Dohme | Meals · 2023-07-12 | Keytruda | $25 |
| Merck Sharp & Dohme | Meals · 2023-04-12 | Keytruda | $24 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1174978852
- Licence
- CA A181751California A181751: Current · expires 2026-09-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2016-04-29
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 234 Goodman St, Cincinnati, OH, 45219